Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4697
Peer-review started: May 7, 2021
First decision: June 6, 2021
Revised: June 8, 2021
Accepted: July 7, 2021
Article in press: July 7, 2021
Published online: July 28, 2021
Endoscopic biliary stenting is an established procedure for patients with biliary strictures. However, complications such as stent occlusion and stent-related cholangitis after stent placement may worsen the quality of patients’ life. Since duodenobiliary reflux is a major cause of those complications, the design of stents with an anti-reflux valve is a potential solution for reducing duodenobiliary reflux.
The authors have previously developed a new anti-reflux plastic stents (ARPSs) and conducted a clinical trial to compare the patency of ARPSs with that of traditional plastic stents (TPSs), which showed this new ARPS had a significantly longer stent patency. However, the role of this new ARPS in reducing the onset of stent-related cholangitis compared with TPS remains unknown.
In this study, the authors compared this new ARPS with TPS in patients with biliary strictures.
The authors retrospectively reviewed the data of consecutive patients with biliary strictures who underwent first endoscopic biliary stenting between February 2016 and May 2019 at West China Hospital, Sichuan University from our prospectively collected database. According to the inclusion and exclusion criteria, eligible patients were included for analysis. The onset of stent-related cholangitis, stent patency, clinical success, and other adverse events were evaluated.
During the study period, 67 patients in the ARPS group and 66 patients in the TPS group were included. There was a significant difference when comparing the onset of stent-related cholangitis, which was significantly lower in the ARPS group than in the TPS group. The cumulative median stent patency in the ARPS group was significantly longer than that in the TPS group. No significant differences were noted in the rates of clinical success and other adverse events between both groups.
This new ARPS results in superior to TPS in reducing the risk of stent-related cholangitis and prolonging stent patency.
Multicenter studies with large samples are expected to evaluate further the safety and efficacy of this new ARPS.